Prevagen Reviews: Does It Work? The FTC Ruling Explained

Apoaequorin, the jellyfish protein sold as Prevagen, is a protein taken by mouth — digested to amino acids like any other, with no credible mechanism by which it reaches the brain intact. The manufacturer’s own Madison Memory Study is the basis of the FTC’s deception case: the agency alleged that of more than 30 post-hoc subgroup comparisons, a handful reached nominal significance by chance. In December 2024, after a jury trial, the US District Court for the Southern District of New York ordered Quincy Bioscience to stop making the deceptive memory and cognitive-improvement claims.

Written by the Fog & Clarity editorial team · Published 12 July 2026 · Last updated 12 July 2026

The claim

The marketing proposition is unusually specific for this category: a calcium-binding protein originally isolated from the jellyfish Aequorea victoria supports memory, with the benefit framed in terms of memory improvement over a defined period. That specificity is what made it commercially effective, and it is also what regulators litigated over.

What follows is what is documented — the trial, the statistical objection, and the court record. We are not making an assertion about the company’s intent or about what any individual customer experienced, and this page carries no product link of any kind.

Where it came from

The scientific story starts with a real piece of biology. Apoaequorin is the protein component of aequorin, a calcium-binding photoprotein from a bioluminescent jellyfish, and it is a genuine laboratory reagent. The marketing inference — that a protein which binds calcium in a test tube will regulate calcium in human neurons when swallowed — skips the step where the protein has to survive digestion and cross the blood-brain barrier.

It does not. A protein consumed orally is broken down into amino acids by gastric and pancreatic enzymes, and those amino acids are indistinguishable from any other dietary protein. There is no credible mechanism by which apoaequorin arrives in the brain in a form that could do anything specific.

This matters beyond one product. Orally administered proteins are a recurring theme in supplement marketing precisely because a protein sounds more sophisticated than a plant extract, and the digestion problem is easy to leave unmentioned. The question to ask of any such product is simple and rarely answered: what reaches the brain, in what form, and which study measured it.

The commercial story is the Madison Memory Study — a company-run trial that produced the numbers used in advertising. The FTC and the New York Attorney General sued Quincy Bioscience in January 2017 over the memory and cognition claims built on it.¹²

What the evidence actually shows

The statistical objection is the heart of it, and it is worth understanding because the same pattern appears throughout this category. When a trial’s primary comparison does not reach significance, one option is to slice the participants into subgroups after the fact and test again. Run enough of those comparisons and some will cross the conventional significance threshold by chance alone — that is what a 5% threshold means. The FTC alleged that the study analysed more than 30 post-hoc subgroup comparisons and that a handful of nominally significant results emerged in exactly the way chance predicts.²

The litigation ran for close to eight years. In December 2024, following a jury trial, the US District Court for the Southern District of New York ordered the company to stop making the deceptive memory and cognitive-improvement claims.¹³ That is the documented outcome, stated as narrowly as the record supports it.

Element	What is documented
Evidence tier	Insufficient/negative — no credible mechanism, and the supporting trial is the subject of a deception case¹
Mechanism	An orally consumed protein, digested to amino acids. No demonstrated route to the brain intact
Key trial	The Madison Memory Study, run by the manufacturer; the FTC alleged more than 30 post-hoc subgroup comparisons²
Regulatory action	FTC and NY Attorney General suit filed January 2017³
Court outcome	December 2024: SDNY ordered the marketer to stop the deceptive memory and cognitive-improvement claims after a jury trial¹
Population with a demonstrated effect	None

What a positive result looks like when it is real

The comparison is instructive. COSMOS randomized thousands of older adults to a daily multivitamin-mineral or placebo for three years, with prespecified endpoints, independent analysis and three separate sub-studies. COSMOS-Mind, with 2,262 participants, found global cognition improving relative to placebo — a slowing of cognitive aging estimated at roughly 60%, about 1.8 years over three years. COSMOS-Web, with more than 3,500 participants, found a memory benefit at one year sustained through three.⁴⁵⁶

Note what that trial did not need: a novel protein, a proprietary blend, or a subgroup analysis to rescue the result. Note also what it produced — a modest effect from a cheap generic product, described in years rather than in adjectives. The same trial found no cognitive effect from its cocoa flavanol arm across more than 5,700 participants, and reported that too.⁴

Why this case shapes how we write

The Prevagen litigation is the reason this site never states a number of years of memory “restored” or “reversed” about any product, and never treats a manufacturer-run study as sufficient on its own. It is also why our evidence tiers weight independent replication so heavily: a single positive result from the party selling the product is the weakest form of evidence that still counts as evidence at all.

It also settles what we do with a study we cannot fully inspect. The Madison Memory Study is the load-bearing evidence for a product sold at scale, and the public dispute about it was never whether the participants existed — it was about which comparisons were planned before the data arrived and which were chosen afterwards. That distinction is invisible from a summary or a press release. Where a product’s only support is a manufacturer-run study whose analysis plan is not public, the honest tier is insufficient rather than promising, and “no evidence exists” is a publishable answer rather than a gap to be filled with hedging.

⚠️ Memory change is a clinical question, not a shopping one

If you or someone in your family is worried about memory, the useful next step is a doctor, not a shelf. Several genuinely treatable causes produce memory symptoms — B12 deficiency in particular, which is common in adults over 50, vegans, people taking metformin and people on long-term acid suppression, and which can cause irreversible neurological damage if it goes untreated.⁷ Those are identified by testing. No supplement substitutes for that assessment.

Why the claim persists

The category is unusual, and unusual sounds like innovation. Jellyfish protein is memorable in a way that “multivitamin” is not, and novelty is easily mistaken for evidence of a new mechanism.

Enforcement took eight years. The complaint was filed in January 2017; the order came in December 2024. For that entire period the product was on pharmacy shelves, and the case was a legal proceeding rather than a recall.

Memory complaints are self-limiting and variable. Everyday forgetfulness fluctuates with sleep, stress and workload. Anyone starting a product during a bad stretch is likely to improve afterwards regardless of what they took — which is exactly why placebo-controlled trials exist, and why a prespecified primary endpoint matters more than a subgroup that looked good afterwards.

Community reports — not trial data

This product has a large number of enthusiastic customer reviews. Those reviews are real in the sense that people wrote them, and they cannot distinguish a drug effect from expectation, regression to the mean, or the ordinary variability of everyday memory. That is not a criticism of the people writing them. It is the reason blinding and a control group were invented, and the reason testimonials do not appear in our evidence tiers.

What to do instead

Take memory concerns to a clinician. Reversible causes exist and are found by testing — B12 status, thyroid function, medication review, sleep and mood.
If you want the intervention with the best trial behind it, a plain daily multivitamin-mineral in adults over 65 is it. Check the B6 content on the panel.
Ask three questions of any study a product cites: who ran it, was the primary endpoint prespecified, and has anyone independent replicated it.
Treat a specific number of “years of memory restored” as a warning label. That exact framing is what the FTC litigated over — see our red-flag list.
Start from the evidence. The tier list gives every compound a rating and names the population each effect was found in.

What would change our mind

Two things, and they are separable. First, a demonstration that orally administered apoaequorin reaches the brain intact, or that a specific digestion product of it has a defined cognitive action — the mechanism problem has to be solved before any efficacy claim is interpretable. Second, an adequately powered, preregistered, independently funded randomized trial with a prespecified primary cognitive endpoint, published in full and replicated by a group with no commercial relationship to the manufacturer. Neither exists today.

Frequently asked questions

What did the court actually rule about Prevagen?

In December 2024, after a jury trial, the US District Court for the Southern District of New York ordered Quincy Bioscience to stop making the deceptive memory and cognitive-improvement claims. The FTC published a statement on the outcome. That is the documented finding; we do not characterize it beyond that.

Is apoaequorin dangerous?

Safety is not the issue this case is about — it is a protein, digested like other dietary protein. The issue is efficacy claims that the evidence did not support. The practical harm is opportunity cost: money spent, and time not spent investigating a memory complaint that might have a treatable cause.

What is wrong with post-hoc subgroup analysis?

Nothing, if it is labelled as hypothesis-generating. The problem is treating it as confirmation. Testing 30 comparisons at a 5% threshold produces roughly one or two nominally significant results by chance even when the treatment does nothing, which is why a prespecified primary endpoint is the thing that counts.

Does any memory supplement have real trial evidence?

A daily multivitamin-mineral in adults over 65 has the best of it, from COSMOS. Beyond that, effects are small and tied to specific populations — creatine in adults aged 66 to 76, where the memory effect reached a standardized mean difference of 0.88 against roughly zero in people under 31⁸; bacopa after twelve weeks or more of a standardized extract⁹; caffeine with L-theanine for a few hours of attention and task-switching accuracy¹⁰. Nothing in this field earns a strong rating for improving cognition in healthy adults.

Sources

These statements have not been evaluated by the Food and Drug Administration. Nothing here is intended to diagnose, treat, cure or prevent any disease.

This article is information, not medical advice. Talk to a doctor or pharmacist about your own situation, especially if you take prescription medication.